Literature DB >> 28138804

LOVA: the role of endoscopic third ventriculostomy and a new proposal for diagnostic criteria.

Guillermo Ibáñez-Botella1, Laura González-García2, Antonio Carrasco-Brenes2, Bienvenido Ros-López2, Miguel Ángel Arráez-Sánchez2.   

Abstract

The diagnostic criteria and management of this condition continue to be a topic of debate in the literature. The term definitive symptomatic LOVA (longstanding overt ventriculomegaly in adults) is applied to patients that fulfil a series of diagnostic criteria,which are reviewed in our paper. The main subject of our study is to propose a rearrangement of the criteria for the diagnosis of this entity and adjusted treatment strategies. We present our data evaluating the role of endoscopy in this pathology. This descriptive and analytical study comprised 27 adult patients with LOVA who underwent endoscopic third ventriculostomy (ETV). Data regarding age, gender and onset of symptoms, a previously implanted shunt, clinical examination and radiological findings at the time of diagnosis, and the intracranial pressure (ICP) recordings in some cases, were carefully retrospectively reviewed. ETV success was determined based on clinical state and radiological criteria. ETV was performed in all 27 cases. Mean follow up period was 4.2 years (6 months to 8 years). 2/27 patients (7.40%) were lost to follow-up. The overall success rate for ETV was 76% (21/25 patients). ETV resulted in shunt independency in two of the three patients with a previous shunt. Based on our results, we believe that ETV must be considered as the treatment of choice for patients with symptomatic LOVA.

Entities:  

Keywords:  Endoscopic third ventriculostomy; Hydrocephalus; LOVA; Longstanding overt ventriculomegaly in adults; Neuroendoscopy

Mesh:

Year:  2017        PMID: 28138804     DOI: 10.1007/s10143-017-0813-4

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   3.042


  18 in total

1.  Pathophysiology of long-standing overt ventriculomegaly in adults.

Authors:  S Oi; M Shimoda; M Shibata; Y Honda; K Togo; M Shinoda; R Tsugane; O Sato
Journal:  J Neurosurg       Date:  2000-06       Impact factor: 5.115

Review 2.  Ventricular shunt infections: immunopathogenesis and clinical management.

Authors:  Yenis Gutierrez-Murgas; Jessica N Snowden
Journal:  J Neuroimmunol       Date:  2014-08-13       Impact factor: 3.478

3.  Clinical features of late-onset idiopathic aqueductal stenosis.

Authors:  T Fukuhara; M G Luciano
Journal:  Surg Neurol       Date:  2001-03

4.  Failed endoscopic third ventriculostomy in children: management options.

Authors:  Aaron Mohanty; M K Vasudev; S Sampath; S Radhesh; V R Sastry Kolluri
Journal:  Pediatr Neurosurg       Date:  2002-12       Impact factor: 1.162

5.  [Usefulness of continuous intracranial pressure monitoring in long-standing overt ventriculomegaly in adults].

Authors:  Ángel Horcajadas Almansa; Nicolás Cordero Tous; Ana Román Cutillas; Ana Jorques Infante; Enrique Saura Rojas; Benjamín Iáñez Velasco; Carlos Sánchez Corral
Journal:  Neurocirugia (Astur)       Date:  2014-11-24       Impact factor: 0.553

6.  Gravitational shunts in longstanding overt ventriculomegaly in adults.

Authors:  Michael Kiefer; Regina Eymann; Martin Strowitzki; Wolf-Ingo Steudel
Journal:  Neurosurgery       Date:  2005-07       Impact factor: 4.654

7.  Failure of third ventriculostomy in the treatment of aqueductal stenosis in children.

Authors:  G Cinalli; C Sainte-Rose; P Chumas; M Zerah; F Brunelle; G Lot; A Pierre-Kahn; D Renier
Journal:  J Neurosurg       Date:  1999-03       Impact factor: 5.115

8.  Longstanding overt ventriculomegaly in adults: pitfalls in treatment with endoscopic third ventriculostomy.

Authors:  Harold L Rekate
Journal:  Neurosurg Focus       Date:  2007-04-15       Impact factor: 4.047

9.  A randomized controlled dual-center trial on shunt complications in idiopathic normal-pressure hydrocephalus treated with gradually reduced or "fixed" pressure valve settings.

Authors:  Terje Sæhle; Dan Farahmand; Per Kristian Eide; Magnus Tisell; Carsten Wikkelsö
Journal:  J Neurosurg       Date:  2014-09-05       Impact factor: 5.115

Review 10.  Ventriculostomy for treatment of hydrocephalus.

Authors:  J M Drake
Journal:  Neurosurg Clin N Am       Date:  1993-10       Impact factor: 2.509

View more
  5 in total

1.  Open-aqueduct LOVA, LIAS, iNPH: a comparative clinical-radiological study exploring the "grey zone" between different forms of chronic adulthood hydrocephalus.

Authors:  Giorgio Palandri; Alessandro Carretta; Emanuele La Corte; Giulia Giannini; Matteo Martinoni; Paolo Mantovani; Luca Albini-Riccioli; Caterina Tonon; Diego Mazzatenta; Benjamin D Elder; Alfredo Conti
Journal:  Acta Neurochir (Wien)       Date:  2022-04-27       Impact factor: 2.816

2.  Surgical Treatment of Long-Standing Overt Ventriculomegaly in Adults (LOVA): A Comparative Case Series between Ventriculoperitoneal Shunt (VPS) and Endoscopic Third Ventriculostomy (ETV).

Authors:  Nicola Montemurro; Antonino Indaimo; Davide Tiziano Di Carlo; Nicola Benedetto; Paolo Perrini
Journal:  Int J Environ Res Public Health       Date:  2022-02-09       Impact factor: 3.390

3.  Long-standing overt ventriculomegaly in adulthood with primary presentation of psychiatric disturbance: A case report.

Authors:  Gao-Jian Su; Jie Gao; Chu-Wei Wu; Jun-Feng Zou; Dong-Liang Zhu; Jun Liu; Jie-Hua Zhang; Xian-Jian Huang
Journal:  Medicine (Baltimore)       Date:  2021-12-10       Impact factor: 1.817

4.  A case of aqueductal obstruction by web with no sign except a headache.

Authors:  Fariba Zarei; Banafsheh Zeinali-Rafsanjani; Pooya Iranpour; Sepideh Sefidbakht
Journal:  Radiol Case Rep       Date:  2022-08-05

5.  How should we treat long-standing overt ventriculomegaly in adults (LOVA)? A retrospective cohort study.

Authors:  Conor S Gillespie; George E Richardson; Mohammad A Mustafa; Daisy Evans; Alan M George; Abdurrahman I Islim; Conor Mallucci; Michael D Jenkinson; Catherine J McMahon
Journal:  Neurosurg Rev       Date:  2022-06-11       Impact factor: 2.800

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.